Article

OBJECTIVE: To study plasma levels of matrix metalloproteinases (MMPs) as
potential markers of recovery during intensive rehabilitation therapy (IRT) after
stroke. DESIGN: Prospective and descriptive 3-month follow-up study. SETTING:
Rehabilitation unit and research center. PARTICIPANTS:
Patients with first-ever
ischemic stroke (n=15) enrolled to IRT (>/=3h/d and 5d/wk) and healthy volunteers
(n=15) (N=30). INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: The primary
outcome was to measure plasma MMP3, MMP12, and MMP13 levels and evaluate
potential associations with motor/functional scales using a battery of tests
(National Institutes of Health Stroke Scale, modified Rankin scale, Barthel
Index, Fugl-Meyer Assessment, Functional Ambulation Categories, Medical Research
Council scale, Chedoke Arm and Hand Activity Inventory, and the 10-m walk test)
before IRT and at 1- and 3-month follow-ups. The secondary outcome was to
evaluate the use of these MMPs as biomarkers as predictors of patient's outcome.
RESULTS: MMP levels remained stable during the study period and were similar to
those in the healthy volunteer group. However, baseline MMP12 and MMP13 levels
were strongly associated with stroke severity and were found to be elevated in
those patients with the poorest outcomes. Interestingly, plasma MMP3 was
independent of baseline stroke characteristics but was found to be increased in
patients with better motor/functional recovery and in patients with larger
improvements during rehabilitation. CONCLUSIONS: MMPs might act as biologic
markers of recovery during rehabilitation therapy related to their roles in both
injury and tissue remodeling. Future confirmatory investigations in multicenter
studies are warranted by our data.
CI - Copyright (c) 2016 American Congress of Rehabilitation Medicine. Published by
Elsevier Inc. All rights reserved.

Langue : ANGLAIS